BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15993068)

  • 1. 2-Aminoquinazoline inhibitors of cyclin-dependent kinases.
    Bathini Y; Singh I; Harvey PJ; Keller PR; Singh R; Micetich RG; Fry DW; Dobrusin EM; Toogood PL
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3881-5. PubMed ID: 15993068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
    Kubo A; Nakagawa K; Varma RK; Conrad NK; Cheng JQ; Lee WC; Testa JR; Johnson BE; Kaye FJ; Kelley MJ
    Clin Cancer Res; 1999 Dec; 5(12):4279-86. PubMed ID: 10632371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
    Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
    J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity.
    Aubry C; Jenkins PR; Mahale S; Chaudhuri B; Maréchal JD; Sutcliffe MJ
    Chem Commun (Camb); 2004 Aug; (15):1696-7. PubMed ID: 15278142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
    Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
    Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of novel inhibitors of cyclin-dependent kinases.
    Kent LL; Hull-Campbell NE; Lau T; Wu JC; Thompson SA; Nori M
    Biochem Biophys Res Commun; 1999 Jul; 260(3):768-74. PubMed ID: 10403840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.
    VanderWel SN; Harvey PJ; McNamara DJ; Repine JT; Keller PR; Quin J; Booth RJ; Elliott WL; Dobrusin EM; Fry DW; Toogood PL
    J Med Chem; 2005 Apr; 48(7):2371-87. PubMed ID: 15801830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of cyclin-dependent kinase 4 during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1.
    Phelps DE; Xiong Y
    Cell Growth Differ; 1998 Aug; 9(8):595-610. PubMed ID: 9716177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors.
    Lee J; Choi H; Kim KH; Jeong S; Park JW; Baek CS; Lee SH
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2292-5. PubMed ID: 18353638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
    Rao S; Lowe M; Herliczek TW; Keyomarsi K
    Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
    McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
    Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
    Said TK; Medina D
    Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic approaches to indolo[6,7-a]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors.
    Faul MM; Engler TA; Sullivan KA; Grutsch JL; Clayton MT; Martinelli MJ; Pawlak JM; LeTourneau M; Coffey DS; Pedersen SW; Kolis SP; Furness K; Malhotra S; Al-awar RS; Ray JE
    J Org Chem; 2004 Apr; 69(9):2967-75. PubMed ID: 15104433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
    Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
    J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity.
    Sotillo R; Renner O; Dubus P; Ruiz-Cabello J; Martín-Caballero J; Barbacid M; Carnero A; Malumbres M
    Cancer Res; 2005 May; 65(9):3846-52. PubMed ID: 15867383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents.
    Ryu CK; Kang HY; Lee SK; Nam KA; Hong CY; Ko WG; Lee BH
    Bioorg Med Chem Lett; 2000 Mar; 10(5):461-4. PubMed ID: 10743948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
    Engler TA; Furness K; Malhotra S; Sanchez-Martinez C; Shih C; Xie W; Zhu G; Zhou X; Conner S; Faul MM; Sullivan KA; Kolis SP; Brooks HB; Patel B; Schultz RM; DeHahn TB; Kirmani K; Spencer CD; Watkins SA; Considine EL; Dempsey JA; Ogg CA; Stamm NB; Anderson BD; Campbell RM; Vasudevan V; Lytle ML
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2261-7. PubMed ID: 12824014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.
    Misra RN; Xiao HY; Williams DK; Kim KS; Lu S; Keller KA; Mulheron JG; Batorsky R; Tokarski JS; Sack JS; Kimball SD; Lee FY; Webster KR
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2973-7. PubMed ID: 15125971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Cdk inhibitors restore TGF-beta sensitivity in cdk4 overexpressing epithelial cells.
    Soni R; Fretz H; Muller L; Schoepfer J; Chaudhuri B
    Biochem Biophys Res Commun; 2000 Jun; 272(3):794-800. PubMed ID: 10860833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.